These effects suggest that the final site-specific DNA methylation pattern of tissue-specific genes is defined through a continuous, relatively fast interplay between active DNA demethylation and re-methylation mechanisms.
The aim of this work was to study, during muscle differentiation, the structural and temporal variation of the methylation pattern of myogenin. We used, for this purpose, the Hpa II / PCR technique (55, 56), optimized as a multiplex assay, to study the methylation status of a single CpG site of myogenin 5'-flanking region and of the three CpG sites of exon 1, and relate our findings to the transcriptional activation of this gene. We demonstrated a strong correlation between the temporal dynamics of demethylation of the sole CpG site of the 5'-flanking region and myogenin expression. In vivo, the myogenin 5'-flanking region was found to be fully methylated in non-muscle tissues, partially methylated in adult muscle (where no myogenin expression was detected), and demethylated in fetal muscle where, by contrast, myogenin was expressed at high levels. The fact that the dynamics of hypomethylation induction in vitro did not last nearly as long as the cell cycle supports the idea of active demethylation mechanisms. However, the presence of 3-deaza-adenosine, an inhibitor of biological methylation reactions based on the AdoMet metabolism (33, 57) , together with homocysteine to enhance its inhibitory effect, further shortened the duration of the dynamics of demethylation, which suggests that re-methylation mechanisms are also involved. These findings point, as far as myogenin is concerned, to: 1) an interplay between active demethylation and remethylation mechanisms in the definition of the final methylation pattern of the gene and 2) a physiological role, in the definition of the transcriptional status of this gene, of the demethylation dynamics of the CpG site present in its 5'-flanking region.
The cDNA of rat myogenin, excised from the plasmid BSM13 -MGN#11 (45), was used as a probe for in vitro expression studies by Northern blotting. Blots were normalized with an 18S ribosomal DNA mouse probe cloned in the pBR-322 plasmid (63) . Probes were labeled by random priming (64, 65) using the Megaprime DNA labeling system with [α-32 P]dATP (3000 Ci/mmol; specific activity >1.9 x 10 9 dpm/µg). Radioactive probes were purified by Centri-Sep columns.
Agarose electrophoresis of total RNA, vacuum transfer on Hybond N membrane (Amersham) and crosslinking were performed according to standard procedures (62) . Each membrane was prehybridized in a hybridization oven at 42°C, by shaking for 2 hrs and by rolling for an additional 2 hrs, in 10 ml of 50% Quick Hyb (Stratagene), 50% formamide and 100 µg/ml salmon sperm DNA (Sigma). The radioactive probe was added to the prehybridization solution and the membranes incubated for 18-20 hrs at 42°C in the same oven. Washes were performed with 50 ml of the following buffers: 2x SSC (20x: 175.3 g/l NaCl, 88.2 g/l NaCitrate, pH 7.0), 0.1 % SDS at room temperature; 2x SSC, 0.1 % SDS at 50°C twice; 0.2x SSC, 0.1 % SDS at 55°C twice. Autoradiographs were quantified using a computerized densitometer (BioImage, Genomic Solutions Inc., Ann Arbor, Michigan, USA).
The expression studies in biopsies in vivo were performed by RT-PCR. For this purpose, reverse transcription was performed on 1 µg of total RNA by using, in each 20 µl sample, 50 mM Tris-HCl, pH 8.3, 75 mM KCl, 10 mM dithiothreitol, 3 mM MgCl 2 and 300 µM each of dGTP, dATP, dCTP and dTTP, 20 units of human placental ribonuclease inhibitor, 50 pmol of oligo-d(T) 16 and 50 units of M-MuLV reverse transcriptase at 42°C for 1 hr, followed by heat inactivation at 94°C for 5 min.
In the subsequent amplification reactions, 2 µl of each sample were mixed in a final volume of 50 µl that contained 10 mM Tris-HCl, pH 9.0, 50 mM KCL, 1.5 mM MgCl 2 , 0.1% Triton X-100, 0.01% gelatin and 175 µM each of dGTP, dATP, dCTP and dTTP, with 1 unit of Super Taq DNA polymerase and 20 pmol of each specific primer. For mouse myogenin (GenBank, accession number M95800) and for mouse γ-actin (GenBank, accession number L21996) genes, we performed, using a extracted using a standard phenol/chloroform method followed by ethanol precipitation (62) .
Genomic DNA was treated separately with the following restriction endonucleases: i) EcoR I, which has no recognition sites within the amplified fragments of myogenin gene; ii) Hpa II, which has a recognition site within the 5'-flanking region and three recognition sites within exon 1 (Fig. 1) , and is methylation sensitive (i.e. it fails to cut if the CCGG recognition sequence is methylated at any C).
Exon 3, which possesses no Hpa II or EcoR I recognition sites ( Fig. 1) , was used as an internal Aliquots of the PCR products (15 µl) were examined by electrophoresis in 1.5% agarose gel. Each gel was scanned by a CCD camera and acquired on the BioImage computerized densitometer. The specificity of the fragments was assessed by restriction analysis and/or sequencing. Table I shows the results of differentiation (measured as CK activity) of C2C12 and C2T18 cells. The C2C12 cells showed, after 96 hrs in GM, a low level of CK activity, which, 96 hrs after the shift to DM, underwent a seven-fold increase. The C2T18 clone was characterized by higher CK activity in GM and a further increase after the shift to DM, thereby showing greater myogenic potentialities than C2C12. The presence of the drugs increased the degree of differentiation of both C2C12 and C2T18, the increase being greater in C2T18.
RESULTS

Differentiation -
Myogenin expression in in vitro cell cultures -In GM, C2C12 and C2T18 showed, at early times (48 h), a very low level of myogenin expression, which increased at later times (96 h) ( Fig. 2A and B, lanes 1 and 2). After the shift to DM, myogenin expression was enhanced both in C2C12 and C2T18 ( Fig. 2A and B, lane 3), the final myogenin expression being markedly higher in C2T18 than in C2C12 ( Fig. 2C ). In DM, the drugs produced an increase in myogenin expression both in C2C12 and C2T18 ( Fig. 2A and B, lane 4), with greater effects exerted on the latter clone.
In semiquantitative densitometric assays, the signal intensity was calculated within the blot of scaling the relative signals using the common blot of Figure 2C . The densitometric analysis (Table II) confirmed the qualitative analysis of Northern blot shown in Figure 2 . The C2T18 clone showed, in all conditions, higher signals than the corresponding ones of C2C12. In particular, the increase in myogenin expression of the C2T18 clone after 96 hrs in GM produced a signal comparable to that of C2C12 in DM, while its overall increase in DM, whether with or without drugs, produced the highest myogenin expression. In some experiments the C2T18 signal after 96 hrs in GM reached an intensity as strong as that reached in DM (data not shown). These results further stress the higher myogenic potentiality of C2T18 when compared with C2C12.
The results obtained by Northern blot analysis were confirmed by RT-PCR (data not shown). Figure 3 shows the expression of
Myogenin expression in vivo in biopsies of various tissues -
The same band pattern was obtained both from uncut DNA and from DNA treated with heatinactivated Hpa II (data not shown). In preliminary experiments we also verified that demethylated PCR products, digested with Hpa II and re-amplified after the cut, failed to show any band relative to the 5'-flanking region or exon 1, but produced, by contrast, an amplified product relative to exon 3. In addition, we selected a prolonged extension time (4.5 min) in order to obtain a more efficient amplification of the largest PCR product (499 bp); the result was a signal with an intensity similar to that of the other amplified fragments, regardless of the amount of target DNA used. In C2C12 grown in GM, all the CCGG myogenin sites were methylated up to 48 hrs ( 7A, lane 4). We never observed demethylation of any of the three CCGG sites of exon 1.
Myogenin methylation patterns in in vitro
All the CCGG sites of the C2T18 clone were methylated in GM up to 2 hrs (Fig. 5A, lane 7) .
In all the experiments, the CCGG site of the 5'-flanking region was found to be demethylated after 24
hrs of culture in GM (Fig. 5A, lane 8) . Demethylation was maintained for over 96 hrs in GM. In DM, the C2T18 clone showed early demethylation of the 5'-flanking site 2 hrs after differentiation induction (Fig. 5B, lane 8) , this pattern being maintained for over 72 hrs. Earlier time courses in DM showed methylation of the 5'-flanking site of this clone up to 1 hr after differentiation induction (Fig.   5C , lane 10). In addition, there was no demethylation of the CCGG sites of exon 1 in C2T18.
Myogenin methylation patterns in biopsies of various tissues in vivo -Myogenin was found to
be fully methylated in non-expressing tissues (spleen and brain, Fig. 6 , lanes 7 and 8) and demethylated at the 5'-flanking site in myogenin-expressing embryonic muscle (Fig. 6, lane 10 ). Adult muscle (Fig. 6, lane 9) , where no myogenin expression was found, showed partial demethylation of the 5'-flanking region site, with a band of reduced intensity visible in some preparations. Demethylation in vivo was also strictly limited to the site of the 5'-flanking region.
Myogenin methylation patterns in in vitro cell culture, with drugs -Methylation (up to 8 hrs, Fig. 4C ) of the CCGG 5'-flanking site of C2C12 in DM completely disappeared as early as 2 hrs after differentiation induction in the presence of DH (Fig. 7A, lane 6 ), even in experiments in which some methylation had been found up to 24 hrs after differentiation induction (Fig. 7A, lane 3) ; this demethylated status was maintained for over 72 hrs. These effects were observed only on the CCGG 5'-flanking site, never on the exon 1 CCGG sites.
Clone C2T18 showed a completely demethylated 5'-flanking site from 2 to 72 hrs, whether with (data not shown) or without (as previously shown in Fig. 5B) DH. An earlier time course (Fig.   7B ) showed demethylation of this site after only 20 min, in DM in the presence of DH, whereas controls remained methylated up to 1 hr. The effect was, also in these experiments, strictly limited to the 5'-flanking site.
DISCUSSION
The DNA methylation patterns of MRFs have seldom been studied. MyoD1 plays a fundamental regulatory role in the commitment of the cell to muscle fate; it is expressed both in myoblasts and in myofibers and acts upstream of myogenin which, given that its expression is restricted to terminally differentiated muscle, is instead devoted to the control of final differentiation.
This functional distinction is associated with structural differences in the control region of the two genes, since MyoD1 is associated with a CpG island (48, 66), whereas myogenin is not. Some authors (67) In this work we show that the myogenin expression pattern of C2C12 and C2T18 is strongly correlated with the myogenic potentialities of these cells. The final differentiation levels (evaluated as CK activity) were in fact closely correlated with the final expression levels of myogenin in DM and with the partial induction of myogenin in GM, as well as with its enhanced expression in C2T18. The drugs produced enhanced myogenin expression and a concomitant increase in terminal differentiation, both effects being highest in the C2T18 clone.
Demethylation of myogenin always preceded its activation. The dynamics of the demethylation displayed, in both C2C12 and C2T18, a positive correlation between early demethylation on the one hand, and the levels of myogenin expression and muscle differentiation on the other. After the shift to DM, the 5'-flanking site of myogenin in C2T18, i.e. in the clone with the highest expression of myogenin and the best differentiative ability, was methylated up to 1 hr, but demethylated after 2 hrs, whereas in C2C12 it became demethylated only after 24 hrs. Although GM allowed only limited myogenin expression and muscle differentiation, there was also in this culture condition a good correlation between myogenin demethylation, its expression and muscle differentiation. In fact, higher myogenin expression and muscle differentiation were shown in the C2T18 clone, whose 5'-flanking site was methylated at 2 hrs in GM but demethylated at 24 hrs, than in C2C12, which showed the lowest level of myogenin expression and muscle differentiation in GM combined with a very late methylated status (up to 48 h). However, hypomethylation eventually occurred also in this condition (at 72 h), accounting for the limited effect on myogenin expression and muscle differentiation. By comparing myogenin methylation in DM vs. GM, the demethylation of both C2C12 and C2T18 was found to be anticipated after the shift to DM. Demethylating agents (DH) were able to further anticipate demethylation of the 5'-flanking region site in both clones, concomitantly producing enhanced myogenin expression and terminal differentiation. , is marked hypomethylation due to inhibition of methylating processes. Since passive demethylation mechanisms are unlikely to be involved in the dynamics of demethylation that occurs within a few minutes, some interplay between demethylation and methylation processes must be hypothesized. In our opinion, there may be a balance between active demethylation processes removing the methyl moieties with very fast dynamics on the one hand, and re-methylating mechanisms acting on the same sites, on the other. The equilibrium between these two main mechanisms would produce the final methylation pattern of the gene, thereby defining its transcriptional status. As far as myogenin is concerned, the differentiative stimulus can, by acting on active demethylation processes, lead to early demethylation which is possibly enhanced by a concomitant inhibition of re-methylation processes achieved by drugs acting on the AdoMet metabolism.
The drastic results of the presence or absence of an amplified product relative to the 5'-flanking site, without intermediate signal levels, obtained in almost all the experiments is indicative of a fully methylated or fully demethylated status which requires a very short time interval for transition.
This supports the hypothesis according to which the mechanism involves a DNA demethylase which directly removes the methyl groups from methyl-cytosine residues in DNA (37) and is thought to have the characteristics of a processive enzyme, with the enzyme landing on a molecule of DNA and proceeding to demethylate in cis (71) .
Myogenin demethylation was found to be highly controlled also in a site-specific manner. In fact, the modulation of its methylation was strictly limited to the sole CCGG site of the 5'-flanking region, while the 3 CCGG sites of exon 1 were, by contrast, always methylated. Our results suggest that one site on its own may play a role in the activation of some muscle regulatory genes. Indeed, some methyl-CpG binding proteins show distinct requirements in terms of methyl-CpG density needed for binding, spanning from greater density to single methylated CpG moiety (72) (73) (74) . Interactions between the methyl-CpG density, the location of the methyl-CpG moieties and the promoter strength have also been reported (75-77).
The 5'-flanking region site was also demethylated in embryonic muscle (a myogeninexpressing tissue), but was methylated in non-expressing tissues. These findings substantiate, also in vivo, a role of methylation of the 5'-flanking site in the expression of myogenin. This site was (at least partially) demethylated in adult muscle without evidence of expression, thus confirming previous evidence that DNA demethylation is a condition which is necessary, but is not sufficient, for the complete expression of a gene.
In conclusion, our study suggests that DNA demethylation is an essential active mechanism in the transcriptional control of myogenin, both in vitro and in vivo, and that it is subject to strict site-and time-specific regulation. Demethylation dynamics results from an interplay between demethylating and re-methylating processes and is a crucial variable in the quantitative control of myogenin expression and in muscle terminal differentiation. 
